Sign In
NASDAQ:CNMD
CONMED Corporation Stock Earnings Reports
$61.39
+2.56 (+4.35%)
At Close: Mar 17, 2025
CONMED Earnings Calls
Q4 2024
Beat
$1.34 (11.67%)
| Release date | Feb 05, 2025 |
| EPS estimate | $1.20 |
| EPS actual | $1.34 |
| EPS Surprise | 11.67% |
| Revenue estimate | 341.049M |
| Revenue actual | 345.944M |
| Revenue Surprise | 1.44% |
Q3 2024
Beat
$1.05 (6.06%)
| Release date | Oct 30, 2024 |
| EPS estimate | $0.99 |
| EPS actual | $1.05 |
| EPS Surprise | 6.06% |
| Revenue estimate | 318.13M |
| Revenue actual | 316.701M |
| Revenue Surprise | -0.449% |
Q2 2024
Beat
$0.98 (7.69%)
| Release date | Jul 31, 2024 |
| EPS estimate | $0.91 |
| EPS actual | $0.98 |
| EPS Surprise | 7.69% |
| Revenue estimate | 332.32M |
| Revenue actual | 330.748M |
| Revenue Surprise | -0.473% |
Q1 2024
Beat
$0.790 (6.76%)
| Release date | Apr 24, 2024 |
| EPS estimate | $0.740 |
| EPS actual | $0.790 |
| EPS Surprise | 6.76% |
| Revenue estimate | 306.78M |
| Revenue actual | 311.632M |
| Revenue Surprise | 1.58% |
Last 4 Quarters for CONMED
Below you can see how CNMD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Beat
| Release date | Apr 24, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $70.01 |
| EPS estimate | $0.740 |
| EPS actual | $0.790 |
| EPS surprise | 6.76% |
| Date | Price |
|---|---|
| Apr 18, 2024 | $71.08 |
| Apr 19, 2024 | $72.64 |
| Apr 22, 2024 | $72.61 |
| Apr 23, 2024 | $71.31 |
| Apr 24, 2024 | $70.01 |
| Apr 25, 2024 | $61.90 |
| Apr 26, 2024 | $65.78 |
| Apr 29, 2024 | $67.22 |
| Apr 30, 2024 | $67.98 |
| 4 days before | -1.51% |
| 4 days after | -2.90% |
| On release day | -11.58% |
| Change in period | -4.36% |
Q2 2024
Beat
| Release date | Jul 31, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $69.04 |
| EPS estimate | $0.91 |
| EPS actual | $0.98 |
| EPS surprise | 7.69% |
| Date | Price |
|---|---|
| Jul 25, 2024 | $70.60 |
| Jul 26, 2024 | $71.00 |
| Jul 29, 2024 | $70.08 |
| Jul 30, 2024 | $69.52 |
| Jul 31, 2024 | $69.04 |
| Aug 01, 2024 | $65.34 |
| Aug 02, 2024 | $68.67 |
| Aug 05, 2024 | $65.63 |
| Aug 06, 2024 | $65.42 |
| 4 days before | -2.21% |
| 4 days after | -5.24% |
| On release day | -5.36% |
| Change in period | -7.34% |
Q3 2024
Beat
| Release date | Oct 30, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $65.26 |
| EPS estimate | $0.99 |
| EPS actual | $1.05 |
| EPS surprise | 6.06% |
| Date | Price |
|---|---|
| Oct 24, 2024 | $62.31 |
| Oct 25, 2024 | $62.15 |
| Oct 28, 2024 | $63.76 |
| Oct 29, 2024 | $64.68 |
| Oct 30, 2024 | $65.26 |
| Oct 31, 2024 | $68.24 |
| Nov 01, 2024 | $70.40 |
| Nov 04, 2024 | $70.47 |
| Nov 05, 2024 | $74.01 |
| 4 days before | 4.73% |
| 4 days after | 13.41% |
| On release day | 4.57% |
| Change in period | 18.78% |
Q4 2024
Beat
| Release date | Feb 05, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $74.00 |
| EPS estimate | $1.20 |
| EPS actual | $1.34 |
| EPS surprise | 11.67% |
| Date | Price |
|---|---|
| Jan 30, 2025 | $70.86 |
| Jan 31, 2025 | $71.78 |
| Feb 03, 2025 | $71.21 |
| Feb 04, 2025 | $72.88 |
| Feb 05, 2025 | $74.00 |
| Feb 06, 2025 | $67.36 |
| Feb 07, 2025 | $66.43 |
| Feb 10, 2025 | $67.32 |
| Feb 11, 2025 | $65.06 |
| 4 days before | 4.43% |
| 4 days after | -12.08% |
| On release day | -8.97% |
| Change in period | -8.19% |
CONMED Earnings Call Transcript Summary of Q4 2024
GAAP Net Income
$33.8 million, a slight increase from $33.1 million YoY.
Adjusted Net Income
$41.8 million, up 26.2% YoY; adjusted EPS $1.34, a 26.4% increase.
Full Year Sales
$1.307 billion, up 5.0% YoY (5.3% in constant currency), with Orthopedic and General Surgery businesses seeing varied growth rates.
Business Segment Performance
- Orthopedic Sales: Increased by 2.4% in Q4; 2.5% for the full year.
- General Surgery Sales: Strong growth of 8.7% in Q4; 7.5% for the full year.
- AirSeal: Achieved record sales, expected to continue double-digit growth due to strong demand in robotic and laparoscopic surgeries.
Initiatives and Challenges
- Addressing supply chain issues within the Orthopedic business, with plans to enhance operations through consulting support.
- Expectation for 2025 to focus on resolving supply challenges and operational improvements; leveraging better product mix for profitability.
2025 Guidance
- Revenue Outlook: 4% to 6% growth (constant currency), with reported revenue expected between $1.344 billion to $1.372 billion.
- EPS Guidance: Adjusted EPS projected between $4.25 and $4.40, affected by currency impacts.
- Gross Margin Expectations: Anticipated to remain similar to 2024 due to ongoing operational construction projects and currency headwinds.
Tariff Implications
Changes in tariff negotiations may pose a significant financial impact, particularly if proposed tariffs by the new administration are enacted. Potential impacts have been quantified but remain uncertain.
Long-term Outlook
- Commitment to double EPS growth relative to revenue growth, focusing on improved operational processes.
- Emphasis on product developments, including BioBrace, Buffalo Filter, and the continued success of AirSeal.
Management's Confidence
Leadership expresses optimism about the company's future growth opportunities and strategies to enhance overall portfolio performance. Improvements to be closely monitored over the next several quarters.
Key Takeaways for Investors
- Solid Financial Performance: Recent earnings show solid growth and strong adjusted net income increases.
- Growth Potential in Key Products: AirSeal and other core products are expected to drive future revenue growth significantly.
- Ongoing Supply Chain Challenges: Awareness of operational limitations affecting the Orthopedic segment; management is actively seeking to resolve these.
- Conservative 2025 Guidance: Projected growth rates reflect cautious optimism, with room for potential upside depending on operational improvements.
- Tariff Risk: Tariff implications could affect cost and pricing strategies moving forward.
- Management Vision: Current leadership is focused on turning weaknesses into strengths, refining product offerings, and enhancing profitability over the long term.
CONMED Earnings History
Earnings Calendar
FAQ
When is the earnings report for CNMD?
CONMED Corporation (CNMD) has scheduled its earnings report for Apr 23, 2025 before the markets open.
What is the CNMD price-to-earnings (P/E) ratio?
CNMD P/E ratio as of Mar 17, 2025 (TTM) is 14.30.
What is the CNMD EPS forecast?
The forecasted EPS (Earnings Per Share) for CONMED Corporation (CNMD) for the first fiscal quarter 2025 is $0.81.
What are CONMED Corporation's retained earnings?
On its balance sheet, CONMED Corporation reported retained earnings of $345.94 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
